NASDAQ:ANIK Anika Therapeutics - ANIK Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Anika Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $28.05 +0.55 (+2.00%) (As of 03/23/2023 12:00 AM ET) Add Compare Share Share Today's Range$27.50▼$28.2650-Day Range$25.91▼$32.1052-Week Range$19.95▼$32.51Volume68,089 shsAverage Volume84,323 shsMarket Capitalization$410.37 millionP/E RatioN/ADividend YieldN/APrice Target$28.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Anika Therapeutics MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside1.6% Upside$28.50 Price TargetShort InterestBearish3.69% of Float Sold ShortDividend StrengthN/ASustainability-1.77Upright™ Environmental ScoreNews Sentiment0.63Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.90) to ($0.61) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.42 out of 5 starsMedical Sector918th out of 986 stocksSurgical & Medical Instruments Industry91st out of 100 stocks 1.0 Analyst's Opinion Consensus RatingAnika Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $28.50, Anika Therapeutics has a forecasted upside of 1.6% from its current price of $28.05.Amount of Analyst CoverageAnika Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.69% of the float of Anika Therapeutics has been sold short.Short Interest Ratio / Days to CoverAnika Therapeutics has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Anika Therapeutics has recently increased by 3.22%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAnika Therapeutics does not currently pay a dividend.Dividend GrowthAnika Therapeutics does not have a long track record of dividend growth. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAnika Therapeutics has received a 46.52% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Synthetic bone grafts", "Medical splints", and "Medical screws" products. See details.Environmental SustainabilityThe Environmental Impact score for Anika Therapeutics is -1.77. Previous Next 2.6 News and Social Media Coverage News SentimentAnika Therapeutics has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.35 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Anika Therapeutics this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 1 people have added Anika Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Anika Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.03% of the stock of Anika Therapeutics is held by insiders.Percentage Held by Institutions91.57% of the stock of Anika Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Anika Therapeutics are expected to grow in the coming year, from ($0.90) to ($0.61) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Anika Therapeutics is -27.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anika Therapeutics is -27.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnika Therapeutics has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Anika Therapeutics (NASDAQ:ANIK) StockAnika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company was founded in 1992 and is headquartered in Bedford, MA.Read More Receive ANIK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anika Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ANIK Stock News HeadlinesMarch 22, 2023 | marketwatch.comGlobal Shoulder Labrum Repair Market: Latest Research by Growth Opportunities 2023-2028March 20, 2023 | marketwatch.comGlobal Cosmetic Procedures Market Size by Type (Surgical Procedures, Non-Surgical Procedures) Forecast from 2023 to 2028March 23, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. March 20, 2023 | marketwatch.comOrthobiologics Market Share and Forecast till 2028March 19, 2023 | americanbankingnews.comAnika Therapeutics (NASDAQ:ANIK) Earns Hold Rating from Analysts at StockNews.comMarch 18, 2023 | finance.yahoo.comWe Think Anika Therapeutics (NASDAQ:ANIK) Can Easily Afford To Drive Business GrowthMarch 16, 2023 | marketwatch.comHemostatic Agents Market Share and Forecast till 2028March 15, 2023 | marketwatch.comDisposable Hemostatic Agents Market 2023, Top Factors that Will Boost the Disposable Hemostatic Agents MarketMarch 23, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. March 14, 2023 | marketwatch.comLip Augmentation Market Application, Product, Sales and Forecast 2023-2028March 14, 2023 | marketwatch.comJoint Pain Injections Market Application, Product, Sales and Forecast 2023-2028March 13, 2023 | marketwatch.comCross-linked Hyaluronic Acid Market Size, Growth | Soaring Demand | 2023 - 2029March 12, 2023 | marketwatch.comFacial Aesthetics Market Regional Growth Drivers [2023-2027] | An In-Depth Analysis of Emerging TrendsMarch 10, 2023 | marketwatch.comSoft Tissue Repair Market Application, Product, Sales and Forecast 2023-2028March 8, 2023 | finance.yahoo.comAnika Therapeutics, Inc. (NASDAQ:ANIK) Q4 2022 Earnings Call TranscriptMarch 7, 2023 | benzinga.comAnika Therapeutics shares are trading lower after the company reported Q4 financial results and issued FY23 revenue guidance below analyst estimates.March 6, 2023 | msn.comAnika Therapeutics Non-GAAP EPS of -$0.21 beats by $0.01, revenue of $39.6M beats by $1.89M, guidance below consensusMarch 3, 2023 | msn.comAnika Therapeutics Earnings PreviewMarch 2, 2023 | marketwatch.comNon-Surgical Bio-Implants Market Research Report-Forecast 2023 to 2027February 28, 2023 | marketwatch.comOrthopedic Hyaluronic Acid Market Growing Demand and Trends 2023 to 2028February 22, 2023 | marketwatch.comSports Medicines Market Share : Industry Trends, Growth, Size and Segmentation by 2023 to 2028February 22, 2023 | marketwatch.comJoint Pain Injections Market Outlook and Forecast to 2028February 21, 2023 | reuters.comExclusive: Caligan urges Anika Therapeutics to conduct review, plans board challengeFebruary 21, 2023 | finance.yahoo.comAnika Issues StatementFebruary 21, 2023 | finance.yahoo.comAnika to Issue Fourth Quarter and Year-End 2022 Financial Results on Monday, March 6, 2023February 21, 2023 | finance.yahoo.comUPDATE 1--Caligan urges Anika Therapeutics to conduct review, plans board challengeFebruary 21, 2023 | finance.yahoo.comCaligan Partners Issues Open Letter to Anika BoardSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ANIK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anika Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ANIK Company Calendar Last Earnings11/04/2021Today3/23/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Supplies SectorMedical Current SymbolNASDAQ:ANIK CUSIP03525510 CIK898437 Webwww.anikatherapeutics.com Phone(781) 457-9000Fax781-305-9720Employees297Year Founded1992Price Target and Rating Average Stock Price Forecast$28.50 High Stock Price Forecast$31.00 Low Stock Price Forecast$26.00 Forecasted Upside/Downside+1.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,860,000.00 Net Margins-9.51% Pretax Margin-12.00% Return on Equity-2.43% Return on Assets-1.99% Debt Debt-to-Equity RatioN/A Current Ratio6.07 Quick Ratio4.65 Sales & Book Value Annual Sales$156.24 million Price / Sales2.63 Cash Flow$0.54 per share Price / Cash Flow52.38 Book Value$19.55 per share Price / Book1.43Miscellaneous Outstanding Shares14,630,000Free Float14,190,000Market Cap$410.37 million OptionableOptionable Beta0.86 Social Links Key ExecutivesCheryl Renee BlanchardPresident, Chief Executive Officer & DirectorAnne NunesVice President-OperationsMichael L. LevitzChief Financial Officer, Treasurer & EVPMira LeiwantVP-Quality, Regulatory & Clinical AffairsSteven W. EkVice President-Research & DevelopmentKey CompetitorsOraSure TechnologiesNASDAQ:OSURUtah Medical ProductsNASDAQ:UTMDCerusNASDAQ:CERSAtrionNASDAQ:ATRIMiMedx GroupNASDAQ:MDXGView All CompetitorsInsiders & InstitutionsMetLife Investment Management LLCSold 845 shares on 3/23/2023Ownership: 0.053%Caligan Partners LPBought 591,675 shares on 2/16/2023Ownership: 4.050%Alliancebernstein L.P.Bought 1,115 shares on 2/16/2023Ownership: 0.143%Altshuler Shaham LtdBought 1,957 shares on 2/16/2023Ownership: 0.013%MetLife Investment Management LLCSold 845 shares on 2/15/2023Ownership: 0.053%View All Insider TransactionsView All Institutional Transactions ANIK Stock - Frequently Asked Questions Should I buy or sell Anika Therapeutics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ANIK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ANIK, but not buy additional shares or sell existing shares. View ANIK analyst ratings or view top-rated stocks. What is Anika Therapeutics' stock price forecast for 2023? 2 analysts have issued 1-year target prices for Anika Therapeutics' stock. Their ANIK share price forecasts range from $26.00 to $31.00. On average, they anticipate the company's share price to reach $28.50 in the next twelve months. This suggests a possible upside of 1.6% from the stock's current price. View analysts price targets for ANIK or view top-rated stocks among Wall Street analysts. How have ANIK shares performed in 2023? Anika Therapeutics' stock was trading at $29.60 at the beginning of 2023. Since then, ANIK stock has decreased by 5.2% and is now trading at $28.05. View the best growth stocks for 2023 here. When is Anika Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our ANIK earnings forecast. How were Anika Therapeutics' earnings last quarter? Anika Therapeutics, Inc. (NASDAQ:ANIK) announced its earnings results on Thursday, November, 4th. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.26. The biotechnology company earned $39.54 million during the quarter, compared to analysts' expectations of $36.45 million. Anika Therapeutics had a negative trailing twelve-month return on equity of 2.43% and a negative net margin of 9.51%. During the same period in the prior year, the business earned ($0.45) earnings per share. What ETFs hold Anika Therapeutics' stock? ETFs with the largest weight of Anika Therapeutics (NASDAQ:ANIK) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), Royce Quant Small-Cap Quality Value ETF (SQLV), Principal Healthcare Innovators ETF (BTEC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Vanguard U.S. Minimum Volatility ETF (VFMV) and Dimensional US Marketwide Value ETF (DFUV).Dimensional US Small Cap Value ETF (DFSV). What guidance has Anika Therapeutics issued on next quarter's earnings? Anika Therapeutics issued an update on its FY 2023 earnings guidance on Monday, March, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $158.00 million-$163.00 million, compared to the consensus revenue estimate of $168.40 million. What other stocks do shareholders of Anika Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Alibaba Group (BABA), Broadcom (AVGO), Gilead Sciences (GILD), Micron Technology (MU), Skyworks Solutions (SWKS), Tesla (TSLA), Advanced Micro Devices (AMD), CVS Health (CVS), Enterprise Products Partners (EPD) and Ligand Pharmaceuticals (LGND). What is Anika Therapeutics' stock symbol? Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK." Who are Anika Therapeutics' major shareholders? Anika Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (6.57%), Renaissance Technologies LLC (4.08%), Caligan Partners LP (4.05%), Boothbay Fund Management LLC (2.52%), Geode Capital Management LLC (1.89%) and Portolan Capital Management LLC (1.42%). Insiders that own company stock include Cheryl R Blanchard, David Colleran, James Loerop, Jeffery S Thompson, John B Henneman III, Michael L Levitz and Raymond J Land. View institutional ownership trends. How do I buy shares of Anika Therapeutics? Shares of ANIK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Anika Therapeutics' stock price today? One share of ANIK stock can currently be purchased for approximately $28.05. How much money does Anika Therapeutics make? Anika Therapeutics (NASDAQ:ANIK) has a market capitalization of $410.37 million and generates $156.24 million in revenue each year. The biotechnology company earns $-14,860,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. How many employees does Anika Therapeutics have? The company employs 297 workers across the globe. How can I contact Anika Therapeutics? Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The official website for the company is www.anikatherapeutics.com. The biotechnology company can be reached via phone at (781) 457-9000, via email at investorrelations@anikatherapeutics.com, or via fax at 781-305-9720. This page (NASDAQ:ANIK) was last updated on 3/23/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.